TrialNature communications2025

Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trial.

Shiao-Pei Weathers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.